-

12:34:56 PM

LGND Stock News

LGND - Ligand Pharmaceuticals, Inc.

09/27/23 9:00 AM

Nasdaq : LGND

acquisitionlow float

Ligand Acquires Assets of Novan, Inc. for $12.2 Million

On July 17, 2023, Ligand offered $15 million to acquire all of the assets of Novan as well as to provide up to $15 million in debtor-in-possession financing. In September 2023, the Bankruptcy Court approved a $12.2 million bid from Ligand to purchase berdazimer gel and all the assets related to the NITRICIL™ technology platform, and the rights to the...

RHEA-AI

neutral

09/26/23 5:05 PM

Nasdaq : LGND, IVA

managementlow float

Ligand Appoints Martine Zimmermann to its Board of Directors

Ligand Pharmaceuticals Incorporated announced the appointment of Martine Zimmermann, PharmD, to its Board of Directors as an independent director. Zimmermann has extensive expertise in regulatory affairs at both small and large pharmaceutical organizations, having worked in the United States, Europe and Asia-Pacific. Throughout her career she has been...

RHEA-AI

positive

09/18/23 5:17 PM

Nasdaq : LGND

acquisitionlow float

Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio

Ligand Pharmaceuticals Incorporated announced that it has entered into a merger agreement, pursuant to which its subsidiary, Pelican Technology Holdings, Inc., has become a wholly owned subsidiary of Primrose Bio, Inc.. Primrose Bio is a stand-alone private company focused on synthetic biology. Simultaneous with the merger, Ligand entered into a Purchase...

RHEA-AI

positive

09/01/23 10:02 PM

Nasdaq : LGND

low float

Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Ligand Pharmaceuticals Incorporated today announced that on September 1, 2023, the Human Capital Management and Compensation Committee of Ligand’ s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 50,000 shares of its common stock to one non-executive employee in connection with the employee’ s commencement of...

RHEA-AI

very positive

08/10/23 4:05 PM

Nasdaq : OABI, LGND

earnings

OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights

OmniAb, Inc. today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner program updates. “Our business continued to grow and perform well during the second quarter with advancements in business development and progress across partner programs. Revenue for the second quarter of 2023 was $6.9 million,...

RHEA-AI

neutral

07/27/23 1:30 PM

Nasdaq : LGND

clinical triallow float

Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

Ligand Pharmaceuticals Incorporated announced that its collaborator Merck, known as MSD outside of the United States and Canada, today announced positive topline results from two Phase 3 trials evaluating V116, an investigational 21- valent pneumococcal conjugate vaccine in vaccine-naïve and previously vaccinated individuals.

RHEA-AI

neutral

07/25/23 4:30 PM

Nasdaq : LGND

conferencesearningslow float

Ligand To Report Second Quarter 2023 Financial Results On August 8

Ligand Pharmaceuticals Incorporated will report second quarter 2023 financial results after the close of the U.S. financial markets on Tuesday, August 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Speakers on the call will include Ligand’ s CEO Todd Davis,...

RHEA-AI

positive

07/17/23 8:59 AM

Nasdaq : LGND, NOVN

acquisitionlow float

Ligand Offers $15 Million to Acquire Assets of Novan, Inc.

Ligand Pharmaceuticals Incorporated announced that it has made an offer to acquire the assets of Novan, Inc. for $15 million in cash and provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded. Novan announced earlier today that it has filed for Chapter 11 reorganization and its entry into a stalking horse...

RHEA-AI

neutral

05/16/23 7:30 AM

Nasdaq : LGND, VKTX

clinical triallow float

Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

Ligand Pharmaceuticals Incorporated announced that its partner Viking Therapeutics, Inc. today announced positive top-line results from its Phase 2 b clinical trial of VK2809, a novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis. The study successfully achieved its primary...

RHEA-AI

neutral

05/11/23 7:00 AM

Nasdaq : OABI, LGND

earnings

OmniAb Reports First Quarter 2023 Financial Results and Business Highlights

Revenue for the first quarter of 2023 was $16.9 million, compared with $9.6 million for the same period in 2022, with the increase primarily due to the recognition of a $10.0 million milestone payment related to the first commercial sale of TECVAYLI ® in the European Union. Research and development expense was $13.8 million for the first quarter of 2023,...

RHEA-AI

neutral

1 2 3 4 5 6 7 Next